Phase 2 N=10 Randomized Treatment

Abatacept in the Treatment of Uveitis

Uveitis

Bottom Line

View on ClinicalTrials.gov: NCT01279954 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2019

Primary outcome: Primary: Adverse Events — 0; 0; 0 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Abatacept (Drug)
Age: Pediatric, Adult, Older Adult · 6+ yrs
Sex: All
Sponsor: Oregon Health and Science University
Primary completion: Jun 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Adverse Events	0; 0; 0	—
SECONDARY Number of Participants With Improvement by 2 or More Lines of Best-corrected Visual Acuity	—	—
SECONDARY Number of Participants With Reduction in Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%	6	—
SECONDARY Number of Participants With Control of Ocular Inflammation, as Judged on Clinical Criteria, According to Standard Methods	4	—

Summary

The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.

Eligibility Criteria

Inclusion Criteria

patients with vision-threatening autoimmune uveitis
failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion Criteria

serious concomitant illness that could interfere with the subject's participation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01279954). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.